A biocompatible membrane composite including a cell impermeable layer and a mitigation layer is provided. The cell impermeable layer is impervious to vascular ingrowth and prevents cellular contact from the host. Additionally, the mitigation layer includes solid features. In at least one embodiment, mitigation layer has therein bonded solid features. In some embodiments, the cell impermeable layer and the mitigation layer are intimately bonded or otherwise connected to each other to form a composite layer having a tight/open structure. A reinforcing component may optionally be positioned external to or within the biocompatible membrane composite to provide support to and prevent distortion. The biocompatible membrane composite may be used in or to form a device for encapsulating biological entities, including, but not limited to, pancreatic lineage type cells such as pancreatic progenitors.

An artificial sphincter to be implanted in a urethra, for treating patients suffering from urinary incontinence, includes a container configured to be connected to a wall of a urethra, inside or outside it, a valve unit housed within the container and configured to move from a release configuration to a block configuration and vice-versa. An actuation magnet is movably (rotatably or slidably) arranged between a first and a second position in the container, and is connected to the valve unit such that a predetermined (rotation or translation) movement of the actuation magnet from a first towards a second position, or from the second towards the first position, under the effect of an external manoeuvre magnet, brings the valve unit from the release configuration to the block configuration, where the valve is stably maintained, and from the block configuration to the release configuration, where the valve is stably maintained.

A mesh implant is disclosed and comprises a single sheet, highly porous, adhesion-resistant, tensile surgical implant composed of a gradually biodegradable synthetic polymer material that is electrospun into nanofibers and randomly stacked to form a three-dimensional (3D) mesh. The mesh implant is for tissue repair and hernia repair. The single-sheet design reduces the foreign material that make up the mesh implant, which minimizes mesh implant rejection. The gradually biodegradable nature of the mesh implant guarantees that the mesh stays in place and supports the repaired site long enough until a proper scar tissue has built up, after which the mesh implant disappears from the body, therefore preventing pain and irritability. The 3D design of the nanofibrous network and the high porosity of the mesh implant facilitate cell attachment, infiltration, and proliferation, all necessary for scar tissue formation, mesh integration, wound healing, and proper defect closure.

An endoluminal prosthesis introducer may include an elongate tubular sheath including a reinforced longitudinal segment and a peelable longitudinal segment extending distally from the reinforced segment. An elongate tubular cannula may be disposed within the sheath. Upon application of a force applied to a distal end of the sheath, the peelable segment may progressively split in a proximal direction, and the reinforced segment may longitudinally move relative to the cannula in a distal direction.

A composition and medical implant made therefrom, the composition including a thick diffusion hardened zone, and preferably further including a ceramic layer. Also provided are orthopedic implants made from the composition, methods of making the composition, and methods of making orthopedic implants from the composition.

A stent able to minimize occurrences of strain and stress concentration in a drug coat layer upon expansive deformation of the stent in a radial direction to avoid the possibility of the drug separating from the stent, includes a stent body and a drug coating layer coated on the outside surface of the stent body so that the thickness of the drug coating layer gradually decreases toward a bent portion of the stent.

A medical product comprises a biodegradable filament and a non-biodegradeable coating. The biodegradable filament forms a stent body having a first end portion, a middle portion, and a second end portion opposite the first end portion. The middle portion extends between the first and second end portions. The non-biodegradeable coating encapsulates the at least one biodegradable filament along the middle portion of the stent body. The non-biodegradeable coating forms a barrier such that the non-biodegradeable coating prevents degradation of the at least one biodegradable filament along the middle portion. The first and second end portions are uncoated. After implantation, the end portions of the stent may biodegrade. The middle portion will not biodegrade due to its encapsulation by the non-biodegradeable coating.

Cell encapsulation devices for biological entities and/or cell populations that contain at least one biocompatible membrane composite are provided. The cell encapsulation devices mitigate or tailor the foreign body response from a host such that sufficient blood vessels are able to form at a cell impermeable surface. Additionally, the encapsulation devices have an oxygen diffusion distance that is sufficient for the survival of the encapsulated cells so that the cells are able to secrete a therapeutically useful substance. The biocompatible membrane composite is formed of a cell impermeable layer and a mitigation layer. The cell encapsulation device maintains an optimal oxygen diffusion distance through the design of the cell encapsulation device or through the use of lumen control mechanisms. Lumen control mechanisms include a reinforcing component that is also a nutrient impermeable layer, internal structural pillars, internal tensioning member(s), and/or an internal cell displacing core.

A composition and medical implant made therefrom, the composition including a thick diffusion hardened zone, and preferably further including a ceramic layer. Also provided are orthopedic implants made from the composition, methods of making the composition, and methods of making orthopedic implants from the composition.

A method of improving the fatigue life of a superelastic medical device includes applying a compressive stress to a fatigue critical location of a medical device comprising a superelastic nickel-titanium alloy, where the compressive stress induces a compressive strain of greater than 9% in the fatigue critical location. After inducing the compressive strain, the compressive stress is released. A tensile stress is applied to the fatigue critical location of the medical device, where the tensile stress induces a tensile strain of greater than 9% in the fatigue critical location. After inducing the tensile strain, the tensile stress is released. After application and release of each of the compressive stress and the tensile stress, the fatigue critical location includes a non-zero amount of residual strain, and the medical device may exhibit improved fatigue properties.